Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hainan Zambon Pharmaceutical is the Chinese subsidiary of the Italian multinational pharmaceutical company Zambon. Established in 1998 and headquartered in Haikou, Hainan, the company serves as a vital manufacturing and commercial hub for Zambon's operations in the Asia-Pacific region. Its core business focuses on the production and distribution of high-quality pharmaceutical products in therapeutic areas such as respiratory health, urology, and pain management. The company is best known for its flagship brands, including Fluimucil (N-acetylcysteine) and Monurol (fosfomycin). Hainan Zambon operates a modern manufacturing facility that adheres to international Good Manufacturing Practice (GMP) standards, ensuring the delivery of European-quality healthcare solutions to the Chinese market.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hainan Zambon Pharmaceutical.